fr
Article scientifique
Anglais

Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C

Publié dansJournal of viral hepatitis, vol. 17, no. 12, p. 845-850
Date de publication2010
Résumé

Hepatocellular apoptosis plays a major role in the pathogenesis of chronic hepatitis C. It can be measured noninvasively by determining the circulating levels of cytokeratin-18 fragments. We hypothesized that the effect of antiviral therapy on this parameter will be different in patients with a sustained virological response, relapse (REL) and nonresponse (NR). We quantified cytokeratin-18 fragments in plasma of patients participating in the Swiss Hepatitis C cohort, who received antiviral therapy without stopping because of sides effects. A total of 315 patients were included, 183 with a sustained response, 64 with NR and 68 who relapsed. Mean levels +/-SD of circulating cytokeratin-18 fragments before therapy were 174 +/- 172 U/L for responsders, 188 +/- 145 for nonresponders and 269 +/- 158 U/L for patients who relapsed. The values were significantly higher in the REL group (ANOVA P < 0.006). A sustained response was associated with a significant improvement of the plasma levels (94 +/- 92 U/L, paired test P < 0.000001), whereas there was no improvement in the nonresponder group (183 +/- 158 U/L) and in the relapser group (158 +/- 148 U/L). There was a weak correlation between alanine aminotransferase (ALT) and cytokeratin-18 fragment levels (r(2) = 0.35, P < 0.000001) before therapy but not after therapy and none with hepatitis C virus (HCV) viremia. Successful antiviral therapy results in a significant decrease in circulating levels of cytokeratin-18 fragments arguing for a reduction in hepatocellular apoptosis after clearance of the HCV. Baseline cytokeratin-18 fragment levels are higher in relapsers. Correlations with ALT are weak, suggesting that these two tests measure different but related processes.

Mots-clés
  • Alanine Transaminase/blood
  • Antiviral Agents/*therapeutic use
  • Apoptosis
  • Cohort Studies
  • Hepacivirus/*drug effects/genetics/physiology
  • Hepatitis C, Chronic/*drug therapy/virology
  • Hepatocytes/physiology
  • Humans
  • Keratin-18/*blood
  • RNA, Viral/blood
  • Recurrence
  • Switzerland
  • Treatment Outcome
  • Viral Load/*drug effects
  • Viremia/drug therapy/virology
Citation (format ISO)
SGIER, C. et al. Effect of antiviral therapy on circulating cytokeratin-18 fragments in patients with chronic hepatitis C. In: Journal of viral hepatitis, 2010, vol. 17, n° 12, p. 845–850. doi: 10.1111/j.1365-2893.2009.01251.x
Fichiers principaux (1)
Article
accessLevelRestricted
Identifiants
ISSN du journal1352-0504
486vues
1téléchargements

Informations techniques

Création23/05/2012 08:57:24
Première validation23/05/2012 08:57:24
Heure de mise à jour14/03/2023 17:35:49
Changement de statut14/03/2023 17:35:49
Dernière indexation12/02/2024 20:19:42
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack